Tumoral markers in bladder cancer (Review).
cystoscopy
cytology
non-muscle invasive
urinary biomarkers
urothelial bladder carcinoma
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
10
02
2021
accepted:
12
03
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
ppublish
Résumé
Bladder tumors are frequently diagnosed urologic malignant diseases with an extremely high recurrence rate compared to other neoplastic tumors. Urothelial bladder carcinomas are mostly identified in their incipient form, as non-muscle invasive, but despite that, a third of them develop into aggressive recurrent disease. The diagnosis of bladder carcinoma at this moment is established using cytology and cystoscopy and is a great challenge for clinicians due to the lack of sensitivity. Urinary biomarkers could improve and enhance the diagnosis and screening techniques and determine a more accurate recurrence rate. However, bladder cancer is a heterogeneous disease and the existence of a single marker test with reduced cost is unlikely; thus, until then, the use of a panel of markers to obtain valuable information is inevitable even though suboptimal for use. To improve this deadlock, new biomarker panels should be identified and prepared to equalize the cost-efficiency balance. The present paper is a literature review concerning the most commonly used tumor markers in urinary bladder cancer as well as the most commonly encountered genetic modifications in such patients.
Identifiants
pubmed: 34055072
doi: 10.3892/etm.2021.10205
pii: ETM-0-0-10205
pmc: PMC8145526
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
773Informations de copyright
Copyright © 2020, Spandidos Publications.
Déclaration de conflit d'intérêts
There are no competing interests to declare regarding this study.
Références
Cancer Biomark. 2017;18(1):47-59
pubmed: 27814275
Clin Cancer Res. 2014 Oct 15;20(20):5311-21
pubmed: 25165097
Eur Urol. 2009 Sep;56(3):430-42
pubmed: 19576682
FEBS J. 2014 Apr;281(7):1750-8
pubmed: 24495014
Urol Oncol. 2013 Feb;31(2):219-27
pubmed: 21795071
Eur Urol. 2017 Jun;71(6):961-969
pubmed: 28069289
J Proteome Res. 2012 Dec 7;11(12):5611-29
pubmed: 23082778
Med Sci Monit. 2017 Sep 27;23:4644-4649
pubmed: 28953854
EBioMedicine. 2019 Jun;44:431-438
pubmed: 31122840
World J Urol. 2015 Jan;33(1):105-10
pubmed: 24562316
Urol Oncol. 2018 Dec;36(12):531.e1-531.e8
pubmed: 30322728
Int J Nanomedicine. 2015 Jan 20;10:791-800
pubmed: 25653521
Dis Markers. 2016;2016:7276502
pubmed: 27057081
Tumour Biol. 2017 May;39(5):1010428317701624
pubmed: 28468590
J Cell Mol Med. 2018 May;22(5):2838-2845
pubmed: 29516641
Oncotarget. 2017 Aug 4;8(40):69162-69173
pubmed: 28978187
Urol Int. 2015;95(1):56-64
pubmed: 25662337
Sci Rep. 2018 Jun 15;8(1):9172
pubmed: 29907864
J Proteome Res. 2010 Nov 5;9(11):5803-15
pubmed: 20806971
Eur Urol Oncol. 2018 Sep;1(4):307-313
pubmed: 31100252
BMC Cancer. 2016 Sep 01;16:704
pubmed: 27586786
Epigenomics. 2018 May;10(5):673-687
pubmed: 29692199
Clin Epigenetics. 2018 May 30;10:71
pubmed: 29854012
Cancer Biol Ther. 2006 Aug;5(8):993-1001
pubmed: 16775427
Urol Oncol. 2010 Nov-Dec;28(6):655-61
pubmed: 19375957
Biomark Med. 2016;10(3):243-53
pubmed: 26861974
PLoS One. 2011;6(11):e27840
pubmed: 22132151
Clin Genitourin Cancer. 2016 Oct;14(5):e493-e499
pubmed: 27157639
Tumour Biol. 2015 Dec;36(12):9545-52
pubmed: 26138586
Elife. 2018 Mar 20;7:
pubmed: 29557778
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Acta Cytol. 2006 Sep-Oct;50(5):499-506
pubmed: 17017434
Clin Cancer Res. 2014 Apr 1;20(7):1978-89
pubmed: 24691641
Mutat Res. 2007 May-Jun;635(2-3):105-117
pubmed: 17257890
Cancer Discov. 2019 Apr;9(4):500-509
pubmed: 30578357
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Acta Naturae. 2015 Jul-Sep;7(3):48-54
pubmed: 26483959
Eur Urol. 2014 Feb;65(2):360-6
pubmed: 24018021
J Urol. 2018 Jan;199(1):74-80
pubmed: 28859894
Clin Cancer Res. 2009 Aug 1;15(15):4935-43
pubmed: 19602546
Anticancer Res. 2013 Mar;33(3):779-84
pubmed: 23482744
Urol Int. 2016;96(1):25-31
pubmed: 26338254
Chin J Cancer. 2016 Apr 07;35:36
pubmed: 27056366
Eur J Pharm Sci. 2017 Feb 15;98:70-79
pubmed: 27751843
Int J Cancer. 2001 Nov 20;95(6):364-9
pubmed: 11668518
Mol Cancer. 2015 Nov 14;14:194
pubmed: 26576778
APMIS. 2019 Aug;127(8):545-553
pubmed: 31231851
Mol Cancer Res. 2007 Dec;5(12):1246-53
pubmed: 18171982
OMICS. 2015 Jan;19(1):1-11
pubmed: 25562196
Int J Biol Markers. 2016 Jul 30;31(3):e276-85
pubmed: 26954073
Int J Biol Markers. 2018 Jan;33(1):94-101
pubmed: 29148015
Eur Urol. 2011 Sep;60(3):484-92
pubmed: 21684071
Oncotarget. 2018 Feb 7;9(18):14354-14365
pubmed: 29581849
Rom J Morphol Embryol. 2019;60(1):287-292
pubmed: 31263858
J Exp Med. 2018 Nov 5;215(11):2748-2759
pubmed: 30257862
Mol Cells. 2018 Mar 31;41(3):179-187
pubmed: 29562735
Eur Urol. 2002 Jun;41(6):668-76
pubmed: 12074786
Oncotarget. 2018 Apr 17;9(29):20658-20669
pubmed: 29755679
Clin Lab Med. 2018 Jun;38(2):237-251
pubmed: 29776629
BMC Urol. 2020 Jul 14;20(1):99
pubmed: 32664878
PLoS One. 2016 Jan 22;11(1):e0147236
pubmed: 26800519
J Urol. 2014 Aug;192(2):583-92
pubmed: 24530986